West Pharmaceutical Services, Inc. (WST) Tops Q3 EPS by 2c; Boosts FY12 EPS Outlook
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $327.95 +1.35%
EPS Growth %: +13.0%
Financial Fact:
Operating profit: 51.3M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +13.0%
Financial Fact:
Operating profit: 51.3M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
West Pharmaceutical Services, Inc. (NYSE: WST) reported Q3 EPS of $0.52, $0.02 better than the analyst estimate of $0.50. Revenue for the quarter came in at $303.8 million versus the consensus estimate of $306.91 million.
West Pharmaceutical Services, Inc. sees FY2012 EPS of $2.67-2.72. West Pharmaceutical Services, Inc. sees FY2012 revenue of $1.25-1.27 million, versus the consensus of $1.25 million.
For earnings history and earnings-related data on West Pharmaceutical Services, Inc. (WST) click here.
West Pharmaceutical Services, Inc. sees FY2012 EPS of $2.67-2.72. West Pharmaceutical Services, Inc. sees FY2012 revenue of $1.25-1.27 million, versus the consensus of $1.25 million.
For earnings history and earnings-related data on West Pharmaceutical Services, Inc. (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Pfizer reaffirms 2026 guidance after CFO transition news
- SpaceX receives Baa1 rating from Moody's with stable outlook
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
